CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Context Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.24−0.01 (-2.30%)
Close on Oct 19, 2026
- Market cap
- $22.69M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -32.5% | -46.4% | |
| Return on assets | – | – | -43.4% | |
| Current ratio | – | 0.03 | 8.52 | |
| Debt to equity | – | -0.00 | – | |
| Interest coverage | – | -3.9× | – | |
| Diluted shares | – | 2M | 95M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Context Therapeutics generated $84.34M from operations and spent $78.10K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$84.34M
Used
$78.10K
Capital expenditure$78.10K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$36.12M
- Cash generatingOperating cash flow above zero-$26.39M
- Return on assets improvedROA up on the prior year-166.4% → -36.8%
- Earnings backed by cashOperating cash flow above net income-$26.39M vs -$36.12M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose35.62 → 8.52
- No dilutionShare count did not rise58M → 95M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –